CSF3 and neoplasm: Although the use of a long-acting G-CSF has been shown to improve outcomes versus the use of daily G-CSFs in other tumour types [77, 78], and there are suggestions that the use of pegfilgrastim could lead to improved outcomes for patients with MM [80], the body of evidence is too small to draw firm conclusions.